Eli Lilly announced Monday that its obesity medication Foundayo demonstrated significant effectiveness in reducing obstructive sleep apnea severity during late-stage clinical trials, marking another potential breakthrough in treating a condition affecting 80 million Americans who face limited treatment options beyond cumbersome breathing machines.
Trial Results Point to New Treatment Option
The pharmaceutical company plans to seek Food and Drug Administration approval by year’s end for Foundayo as a treatment for moderate-to-severe obstructive sleep apnea in adults struggling with obesity or excess weight. The daily pill, which launched in April for weight management, joins a growing class of medications showing effectiveness against OSA, a dangerous condition where breathing repeatedly stops during sleep due to blocked airways.
Obstructive sleep apnea creates serious health risks by causing oxygen drops and blood pressure spikes during sleep, potentially leading to hypertension, heart failure, and stroke. Nearly 1 billion adults worldwide suffer from this condition, yet most cases remain undiagnosed. Current treatment options include positive airway pressure machines that many patients find difficult to use consistently, limiting their effectiveness in real-world settings.
$LLY plans to submit Foundayo to the FDA for the treatment of obstructive sleep apnea by the end of 2026
Building on Previous Success
Eli Lilly already broke ground in this treatment area when its weight loss injection Zepbound became the first medication approved specifically for obstructive sleep apnea in December 2024. The success of Foundayo in clinical trials expands the company’s portfolio of solutions for patients facing this widespread but under-treated condition. Dr. Thomas Seck, senior vice president of product development for Lilly Cardiometabolic Health, emphasized the medication’s dual benefit for patients.
The clinical trial evaluated Foundayo through two independent studies, with the first enrolling 363 patients unable to tolerate standard treatment approaches. This research design helps ensure the medication’s effectiveness across different patient populations and circumstances, strengthening the case for regulatory approval and providing hope for Americans seeking alternatives to existing therapies.
What This Means for American Families
The potential approval represents meaningful progress for families dealing with sleep apnea’s ripple effects, from daytime fatigue affecting work performance to increased healthcare costs from related complications. Access to effective oral medications could improve treatment adherence compared to mechanical breathing devices, ultimately reducing the burden of cardiovascular disease and other serious health consequences. With millions of Americans undiagnosed, expanded treatment options may encourage more people to seek help for sleep-related breathing problems affecting their quality of life and long-term health outcomes.